Loading page
Loading page
Loading substance route
Chronic use is considered moderately addictive with a high potential for abuse and can cause psychological dependence. Compulsive redosing is reported as a notable effect during use.
When addiction develops, cravings and withdrawal effects may occur upon sudden cessation of use, though the severity and nature of physical withdrawal symptoms are not well-characterized.
The exact toxic dosage is unknown due to DCK's limited history of human usage. Overdose can result in unconsciousness with associated risks of vomit aspiration, falls, and accidents. Adverse effects including severe injury or death become increasingly likely at higher doses.
Chronic frequent use may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pelvic and bladder pain, hematuria, and incontinence; these effects appear to occur to a lesser extent than with ketamine and can be avoided by limiting use to occasional rather than daily or weekly consumption.
Antibacterial properties have been speculated but only minimally investigated. If real, prolonged frequent use could potentially disrupt gut microbiome or affect immune function, though this has not been confirmed as a concern at reasonable low-frequency use levels.
Dissociatives including DCK carry a risk of adverse psychological reactions such as mania, hypomania, delusions, and confusion. Mania is listed as a potential acute cognitive effect. Risk may be elevated when combined with stimulants.
Deschloroketamine was first described in a 1966 patent filed by Calvin Stevens at Parke-Davis in Michigan. Stevens, who is also credited with the synthesis of ketamine and phencyclidine, outlined the preparation methods for this structurally related compound. Despite this early documentation, the
Controlled under the Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Austria's new psychoactive substances regulation.
Not currently scheduled or controlled under Czech drug legislation. Possession and use are not criminalized.
Classified as an illegal substance under Italian drug control legislation.
Remains unscheduled as of the available information, though regulatory review was scheduled with a plenary hearing set for January 21, 2025.
Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause as an N-alkyl derivative of 2-amino-2-phenylcyclohexanone, added via S.I. 2013/239 effective February 26, 2013. Possession, production, supply, and import are prohibited.
Prohibited under a general ban on arylcyclohexylamines. Production, distribution, and possession are illegal.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production and import with intent to distribute, administration to others, and trading are criminal offenses. Possession is prohibited but not subject to criminal penalties.
Prohibited substance under Latvian controlled substances laws.
Specifically named as a controlled substance under Verzeichnis E of the Swiss narcotics scheduling system.
Not a scheduled substance at the federal level as of July 2017. However, it may be subject to prosecution under the Federal Analogue Act if sold for human consumption due to its structural similarity to ketamine.